Remimazolam (CNS 7056): an Emerging Sedative and General Anaesthetic

Abstract

Remimazolam is a newer drug in the field of anaesthesia. It combines the properties of midazolam and remifentanil. As the name indicates, midazolam is the parent compound of remimazolam which incorporates the pharmacokinetic properties of remifentanil. Remimazolam is an ultra short acting anaesthetic agent/sedative which rapidly shows its effect after injection and also wears off expeditiously after cessation. Therefore, remimazolam’s dosage can be ideally controlled. Since it acts on benzodiazepine receptors, availability of specific antagonist (flumazenil) further adds to its safety in case of overdose.

Keywords

• anaesthesia
• benzodiazepine
• midazolam
• propofol
• sedative